

# Jamie John Kirkham

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8416389/jamie-john-kirkham-publications-by-year.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

116  
papers

13,194  
citations

34  
h-index

114  
g-index

130  
ext. papers

19,970  
ext. citations

3.9  
avg, IF

6.12  
L-index

#	Paper	IF	Citations
116	Protocol for development of a core outcome set for clinical trials in melasma.. <i>BMJ Open</i> , <b>2022</b> , 12, e046953		0
115	Development of a core outcome set for multimorbidity trials in low/middle-income countries (COSMOS): study protocol.. <i>BMJ Open</i> , <b>2022</b> , 12, e051810	3	0
114	Development of core outcome sets and core outcome measures for central visual impairment, visual field loss and ocular motility disorders due to stroke: a Delphi and consensus study.. <i>BMJ Open</i> , <b>2022</b> , 12, e056792	3	
113	Improving peer review of systematic reviews by involving librarians and information specialists: protocol for a randomized controlled trial. <i>Trials</i> , <b>2021</b> , 22, 791	2.8	0
112	Use of core outcome sets was low in clinical trials published in major medical journals. <i>Journal of Clinical Epidemiology</i> , <b>2021</b> , 142, 19-28	5.7	1
111	Breast cancer management pathways during the COVID-19 pandemic: outcomes from the UK 'Alert Level 4' phase of the B-MaP-C study. <i>British Journal of Cancer</i> , <b>2021</b> , 124, 1785-1794	8.7	6
110	Representation of published core outcome sets for research in regulatory guidance: protocol. <i>HRB Open Research</i> , <b>2021</b> , 4, 45	1.2	1
109	Core outcome set for three ophthalmic conditions: a healthcare professional and patient consensus on core outcome sets for amblyopia, ocular motility and strabismus (COSAMS Study). <i>BMJ Open</i> , <b>2021</b> , 11, e042403	3	
108	Postinflammatory hyperpigmentation: protocol for development of a core outcome set for clinical trials. <i>Archives of Dermatological Research</i> , <b>2021</b> , 1	3.3	3
107	Cross-sectional study of preprints and final journal publications from COVID-19 studies: discrepancies in results reporting and spin in interpretation. <i>BMJ Open</i> , <b>2021</b> , 11, e051821	3	3
106	Development of a core outcome set for cutaneous squamous cell carcinoma trials: identification of core domains and outcomes. <i>British Journal of Dermatology</i> , <b>2021</b> , 184, 1113-1122	4	5
105	COHESION: core outcomes in neonatal encephalopathy (protocol). <i>Trials</i> , <b>2021</b> , 22, 125	2.8	1
104	Multi-Round compared to Real-Time Delphi for consensus in core outcome set (COS) development: a randomised trial. <i>Trials</i> , <b>2021</b> , 22, 142	2.8	1
103	Representation of published core outcome sets for research in regulatory guidance: protocol. <i>HRB Open Research</i> , <b>2021</b> , 4, 45	1.2	1
102	Effect of an editorial intervention to improve the completeness of reporting of randomised trials: a randomised controlled trial. <i>BMJ Open</i> , <b>2020</b> , 10, e036799	3	8
101	Assessing uptake of the Harmonising Outcome Measures for Eczema (HOME) Core Outcome Set and recommended instruments. <i>British Journal of Dermatology</i> , <b>2020</b> , 183, 566-568	4	4
100	Outcome reporting bias in Cochrane systematic reviews: a cross-sectional analysis. <i>BMJ Open</i> , <b>2020</b> , 10, e032497	3	2

99	Core Outcome Set for Actinic Keratosis Clinical Trials. <i>JAMA Dermatology</i> , <b>2020</b> , 156, 326-333	5.1	16
98	Systematic examination of preprint platforms for use in the medical and biomedical sciences setting. <i>BMJ Open</i> , <b>2020</b> , 10, e041849	3	21
97	Uptake of core outcome sets by clinical trialists publishing in major medical journals: Protocol. <i>HRB Open Research</i> , <b>2020</b> , 3, 53	1.2	3
96	Reply. <i>American Journal of Obstetrics and Gynecology</i> , <b>2020</b> , 222, 390-391	6.4	
95	Use of composite outcomes facilitate core outcome set uptake in rheumatoid arthritis trials. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 301-302	2.4	0
94	Patient-focused outcomes are infrequently reported in pediatric health information technology trials: a systematic review. <i>Journal of Clinical Epidemiology</i> , <b>2020</b> , 119, 117-125	5.7	2
93	Assessing the effect of interventions for axial spondyloarthritis according to the endorsed ASAS/OMERACT core outcome set: a meta-research study of trials included in Cochrane reviews. <i>Arthritis Research and Therapy</i> , <b>2020</b> , 22, 177	5.7	6
92	Assessing the relevance and uptake of core outcome sets (an agreed minimum collection of outcomes to measure in research studies) in Cochrane systematic reviews: a review. <i>BMJ Open</i> , <b>2020</b> , 10, e036562	3	5
91	STrengthening the Reporting Of Pharmacogenetic Studies: Development of the STROPS guideline. <i>PLoS Medicine</i> , <b>2020</b> , 17, e1003344	11.6	7
90	Uptake of core outcome sets by clinical trialists publishing in major medical journals: Protocol. <i>HRB Open Research</i> , <b>2020</b> , 3, 53	1.2	
89	A Core Outcome Set for the prevention and treatment of fetal GROWth restriction: deVeloPping Endpoints: the COSGROVE study. <i>American Journal of Obstetrics and Gynecology</i> , <b>2019</b> , 221, 339.e1-339.e10	6.4	20
88	Assessing the impact of a research funder's recommendation to consider core outcome sets. <i>PLoS ONE</i> , <b>2019</b> , 14, e0222418	3.7	18
87	Scoping review on interventions to improve adherence to reporting guidelines in health research. <i>BMJ Open</i> , <b>2019</b> , 9, e026589	3	35
86	Navigating the landscape of core outcome set development in dermatology. <i>Journal of the American Academy of Dermatology</i> , <b>2019</b> , 81, 297-305	4.5	24
85	Empirical comparison of univariate and multivariate meta-analyses in Cochrane Pregnancy and Childbirth reviews with multiple binary outcomes. <i>Research Synthesis Methods</i> , <b>2019</b> , 10, 440-451	7.2	5
84	Improvement was needed in the standards of development for cancer core outcome sets. <i>Journal of Clinical Epidemiology</i> , <b>2019</b> , 112, 36-44	5.7	6
83	Systematic review: outcomes and adverse events from randomised trials in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 978-996	6.1	8
82	Pain Measurement in Rheumatic and Musculoskeletal Diseases: Where To Go from Here? Report from a Special Interest Group at OMERACT 2018. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 1355-1359	4.1	1

81	Development of a core outcome set for amblyopia, strabismus and ocular motility disorders: a review to identify outcome measures. <i>BMC Ophthalmology</i> , <b>2019</b> , 19, 47	2.3	8
80	Core outcome sets for prevention and treatment of postpartum haemorrhage: an international Delphi consensus study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , <b>2019</b> , 126, 83-93	3.7	48
79	Industry funding was associated with increased use of core outcome sets. <i>Journal of Clinical Epidemiology</i> , <b>2019</b> , 115, 90-97	5.7	7
78	Value Assessment and Quantitative Benefit-Risk Modelling of Biosimilar Infliximab for Crohn's Disease. <i>Pharmacoeconomics</i> , <b>2019</b> , 37, 1509-1523	4.4	4
77	A survey exploring biomedical editors' perceptions of editorial interventions to improve adherence to reporting guidelines. <i>F1000Research</i> , <b>2019</b> , 8, 1682	3.6	3
76	Core Outcome Set-STANDARDISED Protocol Items: the COS-STAP Statement. <i>Trials</i> , <b>2019</b> , 20, 116	2.8	76
75	Protocol for the development of the STRENGTHENING the REPORTING OF Pharmacogenetic Studies (STROPS) guideline: checklist of items for reporting pharmacogenetic studies. <i>BMJ Open</i> , <b>2019</b> , 9, e030212	3.2	2
74	RoB 2: a revised tool for assessing risk of bias in randomised trials. <i>BMJ, The</i> , <b>2019</b> , 366, l4898	5.9	3792
73	Development of core outcome sets for vision screening and assessment in stroke: a Delphi and consensus study. <i>BMJ Open</i> , <b>2019</b> , 9, e029578	3	4
72	Model-based sensitivity analysis for outcome reporting bias in the meta analysis of benefit and harm outcomes. <i>Statistical Methods in Medical Research</i> , <b>2019</b> , 28, 889-903	2.3	11
71	The transition of adolescents with juvenile idiopathic arthritis or epilepsy from paediatric health-care services to adult health-care services: A scoping review of the literature and a synthesis of the evidence. <i>Journal of Child Health Care</i> , <b>2018</b> , 22, 332-358	2	17
70	A randomized trial comparing three Delphi feedback strategies found no evidence of a difference in a setting with high initial agreement. <i>Journal of Clinical Epidemiology</i> , <b>2018</b> , 93, 1-8	5.7	26
69	Management of medial humeral epicondyle fractures in children: a structured review protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. <i>Trials</i> , <b>2018</b> , 19, 119	2.8	14
68	The effect of outdoor air pollution on the risk of hospitalisation for bronchiolitis in infants: a systematic review. <i>PeerJ</i> , <b>2018</b> , 6, e5352	3.1	6
67	Development of a consensus core dataset in juvenile dermatomyositis for clinical use to inform research. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 241-250	2.4	20
66	Who and why do researchers opt to publish in post-publication peer review platforms? - findings from a review and survey of F1000 Research. <i>F1000Research</i> , <b>2018</b> , 7, 920	3.6	8
65	CYP genetic variants and toxicity related to anti-tubercular agents: a systematic review and meta-analysis. <i>Systematic Reviews</i> , <b>2018</b> , 7, 204	3	5
64	Outcome reporting bias in trials: a methodological approach for assessment and adjustment in systematic reviews. <i>BMJ, The</i> , <b>2018</b> , 362, k3802	5.9	52

63	Citation analysis did not provide a reliable assessment of core outcome set uptake. <i>Journal of Clinical Epidemiology</i> , <b>2017</b> , 86, 153-159	5.7	12
62	Splinting for the non-operative management of developmental dysplasia of the hip (DDH) in children under six months of age. <i>The Cochrane Library</i> , <b>2017</b> ,	5.2	4
61	Development of the Liverpool Adverse Drug Reaction Avoidability Assessment Tool. <i>PLoS ONE</i> , <b>2017</b> , 12, e0169393	3.7	22
60	Influence of genetic variants on toxicity to anti-tubercular agents: a systematic review and meta-analysis (protocol). <i>Systematic Reviews</i> , <b>2017</b> , 6, 142	3	7
59	Do systematic reviews still exclude studies with "no relevant outcome data"?. <i>BMJ, The</i> , <b>2017</b> , 358, j39195	5.9	3
58	Interventions to improve adherence to reporting guidelines in health research: a scoping review protocol. <i>BMJ Open</i> , <b>2017</b> , 7, e017551	3	8
57	Overview of systematic reviews of therapeutic ranges: methodologies and recommendations for practice. <i>BMC Medical Research Methodology</i> , <b>2017</b> , 17, 84	4.7	11
56	The COMET Handbook: version 1.0. <i>Trials</i> , <b>2017</b> , 18, 280	2.8	663
55	A methodological approach for assessing the uptake of core outcome sets using ClinicalTrials.gov: findings from a review of randomised controlled trials of rheumatoid arthritis. <i>BMJ, The</i> , <b>2017</b> , 357, j22625	5.9	54
54	Multivariate and network meta-analysis of multiple outcomes and multiple treatments: rationale, concepts, and examples. <i>BMJ, The</i> , <b>2017</b> , 358, j3932	5.9	102
53	Core Outcome Set-STAndards for Development: The COS-STAD recommendations. <i>PLoS Medicine</i> , <b>2017</b> , 14, e1002447	11.6	242
52	Feasibility study to examine discrepancy rates in prespecified and reported outcomes in articles submitted to The BMJ. <i>BMJ Open</i> , <b>2016</b> , 6, e010075	3	6
51	ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. <i>BMJ, The</i> , <b>2016</b> , 355, i4919	5.9	4396
50	Referral patterns after a seizure admission in an English region: an opportunity for effective intervention? An observational study of routine hospital data. <i>BMJ Open</i> , <b>2016</b> , 6, e010100	3	12
49	Core Outcome Set-STAndards for Reporting: The COS-STAR Statement. <i>PLoS Medicine</i> , <b>2016</b> , 13, e1002148	11.6	251
48	How Much Participant Outcome Data Is Missing from Sight: Findings from a Cohort of Trials Submitted to a German Research Ethics Committee. <i>PLoS ONE</i> , <b>2016</b> , 11, e0157883	3.7	1
47	Multivariate meta-analysis helps examine the impact of outcome reporting bias in Cochrane rheumatoid arthritis reviews. <i>Journal of Clinical Epidemiology</i> , <b>2015</b> , 68, 542-50	5.7	12
46	Development of interferon beta-neutralising antibodies in multiple sclerosis—a systematic review and meta-analysis. <i>European Journal of Clinical Pharmacology</i> , <b>2015</b> , 71, 1287-98	2.8	11

45	A pilot randomised controlled trial to assess the utility of an e-learning package that trains users in adverse drug reaction causality. <i>International Journal of Pharmacy Practice</i> , <b>2015</b> , 23, 447-55	1.7	9
44	Citation analysis: a new approach to assess the uptake of core outcome sets. <i>Trials</i> , <b>2015</b> , 16,	2.8	1
43	COS-STAR: a reporting guideline for studies developing core outcome sets (protocol). <i>Trials</i> , <b>2015</b> , 16, 373	2.8	44
42	Development of an internationally agreed minimal dataset for juvenile dermatomyositis (JDM) for clinical and research use. <i>Trials</i> , <b>2015</b> , 16, 268	2.8	15
41	National Audit of Seizure management in Hospitals (NASH): results of the national audit of adult epilepsy in the UK. <i>BMJ Open</i> , <b>2015</b> , 5, e007325	3	48
40	The Importance of Integration of Stakeholder Views in Core Outcome Set Development: Otitis Media with Effusion in Children with Cleft Palate. <i>PLoS ONE</i> , <b>2015</b> , 10, e0129514	3.7	70
39	The management of Otitis Media with Effusion in children with cleft palate (mOMEnt): a feasibility study and economic evaluation. <i>Health Technology Assessment</i> , <b>2015</b> , 19, 1-374	4.4	34
38	Development of processes allowing near real-time refinement and validation of triage tools during the early stage of an outbreak in readiness for surge: the FLU-CATs Study. <i>Health Technology Assessment</i> , <b>2015</b> , 19, 1-132	4.4	5
37	A review of the handling of missing longitudinal outcome data in clinical trials. <i>Trials</i> , <b>2014</b> , 15, 237	2.8	45
36	How well are the ASAS/OMERACT Core Outcome Sets for Ankylosing Spondylitis implemented in randomized clinical trials? A systematic literature review. <i>Clinical Rheumatology</i> , <b>2014</b> , 33, 1313-22	3.9	32
35	Dexamethasone and haemorrhage risk in paediatric tonsillectomy: a systematic review and meta-analysis. <i>British Journal of Anaesthesia</i> , <b>2014</b> , 113, 23-42	5.4	42
34	A model-based correction for outcome reporting bias in meta-analysis. <i>Biostatistics</i> , <b>2014</b> , 15, 370-83	3.7	23
33	Bias due to selective inclusion and reporting of outcomes and analyses in systematic reviews of randomised trials of healthcare interventions. <i>The Cochrane Library</i> , <b>2014</b> , MR000035	5.2	111
32	Clinical coding of prospectively identified paediatric adverse drug reactions--a retrospective review of patient records. <i>BMC Pharmacology &amp; Toxicology</i> , <b>2014</b> , 15, 72	2.6	3
31	Evidence for the selective reporting of analyses and discrepancies in clinical trials: a systematic review of cohort studies of clinical trials. <i>PLoS Medicine</i> , <b>2014</b> , 11, e1001666	11.6	106
30	Selective reporting bias of harm outcomes within studies: findings from a cohort of systematic reviews. <i>BMJ, The</i> , <b>2014</b> , 349, g6501	5.9	110
29	Adverse drug reactions and off-label and unlicensed medicines in children: a prospective cohort study of unplanned admissions to a paediatric hospital. <i>British Journal of Clinical Pharmacology</i> , <b>2014</b> , 77, 545-53	3.8	51
28	ADRIC: Adverse Drug Reactions In Children a programme of research using mixed methods. <i>Programme Grants for Applied Research</i> , <b>2014</b> , 2, 1-184	1.5	8

27	Can a core outcome set improve the quality of systematic reviews?--a survey of the Co-ordinating Editors of Cochrane Review Groups. <i>Trials</i> , <b>2013</b> , 14, 21	2.8	113
26	Outcome measures in rheumatoid arthritis randomised trials over the last 50 years. <i>Trials</i> , <b>2013</b> , 14, 324	2.8	113
25	Incidence, characteristics and risk factors of adverse drug reactions in hospitalized children - a prospective observational cohort study of 6,601 admissions. <i>BMC Medicine</i> , <b>2013</b> , 11, 237	11.4	54
24	Selective reporting of outcomes in randomised controlled trials in systematic reviews of cystic fibrosis. <i>BMJ Open</i> , <b>2013</b> , 3,	3	26
23	Reporting of harms data in RCTs: a systematic review of empirical assessments against the CONSORT harms extension. <i>BMJ Open</i> , <b>2013</b> , 3, e003436	3	40
22	Adverse drug reactions and off-label and unlicensed medicines in children: a nested case-control study of inpatients in a paediatric hospital. <i>BMC Medicine</i> , <b>2013</b> , 11, 238	11.4	68
21	Cross-sectional study of prescribing errors in patients admitted to nine hospitals across North West England. <i>BMJ Open</i> , <b>2013</b> , 3,	3	45
20	Systematic review of the empirical evidence of study publication bias and outcome reporting bias - an updated review. <i>PLoS ONE</i> , <b>2013</b> , 8, e66844	3.7	585
19	Bias due to selective inclusion and reporting of outcomes and analyses in systematic reviews of randomised trials of healthcare interventions <b>2012</b> ,		3
18	A multivariate meta-analysis approach for reducing the impact of outcome reporting bias in systematic reviews. <i>Statistics in Medicine</i> , <b>2012</b> , 31, 2179-95	2.3	63
17	The reporting of harms in randomized controlled trials of hypertension using the CONSORT criteria for harm reporting. <i>Clinical and Experimental Hypertension</i> , <b>2012</b> , 34, 548-54	2.2	12
16	NATIONAL AUDIT OF SEIZURE MANAGEMENT IN HOSPITALS: INITIAL FINDINGS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2012</b> , 83, A36.3-A36	5.5	2
15	Adverse drug reactions in children--a systematic review. <i>PLoS ONE</i> , <b>2012</b> , 7, e24061	3.7	154
14	Adverse drug reactions causing admission to a paediatric hospital. <i>PLoS ONE</i> , <b>2012</b> , 7, e50127	3.7	49
13	Development and inter-rater reliability of the Liverpool adverse drug reaction causality assessment tool. <i>PLoS ONE</i> , <b>2011</b> , 6, e28096	3.7	110
12	Bias due to changes in specified outcomes during the systematic review process. <i>PLoS ONE</i> , <b>2010</b> , 5, e9810	3.7	96
11	The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. <i>BMJ, The</i> , <b>2010</b> , 340, c365	5.9	697
10	Selective outcome reporting: telling and detecting true lies. The state of the science. <i>Internal and Emergency Medicine</i> , <b>2010</b> , 5, 151-5	3.7	16

9	The use of statistical process control for monitoring institutional performance in trauma care. <i>Journal of Trauma</i> , <b>2008</b> , 65, 1494-501		10
8	A comparison of hospital performance with non-ignorable missing covariates: an application to trauma care data. <i>Statistics in Medicine</i> , <b>2008</b> , 27, 5725-44	2.3	13
7	The patterning of hypodontia in a group of young adults in Sheffield, UK. <i>Archives of Oral Biology</i> , <b>2005</b> , 50, 287-91	2.8	16
6	Stage 1 Registered Report. Interventions for improving the design and conduct of scientific research: A scoping review. <i>NIHR Open Research</i> , 2, 4		
5	A survey exploring biomedical editors' perceptions of editorial interventions to improve adherence to reporting guidelines. <i>F1000Research</i> , 8, 1682	3.6	3
4	A systematic examination of preprint platforms for use in the medical and biomedical sciences setting		8
3	Comparison of preprints and final journal publications from COVID-19 Studies: Discrepancies in results reporting and spin in interpretation		2
2	Representation of published core outcome sets for research in regulatory guidance: protocol. <i>HRB Open Research</i> , 4, 45	1.2	3
1	Using behavioural science to enhance use of core outcome sets in trials: protocol. <i>HRB Open Research</i> , 5, 23	1.2	